Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial
Chun-Yuan Lin, Sun-Yuan Liang, Yue‐Cune Chang, et al.
The World Journal of Biological Psychiatry (2015) Vol. 18, Iss. 5, pp. 357-368
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Brain NMDA Receptors in Schizophrenia and Depression
Albert Adell
Biomolecules (2020) Vol. 10, Iss. 6, pp. 947-947
Open Access | Times Cited: 166
d-glutamate and Gut Microbiota in Alzheimer’s Disease
Chun-Hung Chang, Chieh‐Hsin Lin, Hsien‐Yuan Lane
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 8, pp. 2676-2676
Open Access | Times Cited: 151
Sodium Benzoate—Harmfulness and Potential Use in Therapies for Disorders Related to the Nervous System: A Review
Łucja Justyna Walczak-Nowicka, Mariola Herbet
Nutrients (2022) Vol. 14, Iss. 7, pp. 1497-1497
Open Access | Times Cited: 87
The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia
Daniela L. Uliana, João Roberto Lisboa, Felipe V. Gomes, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116298-116298
Closed Access | Times Cited: 18
Benzoate and Sorbate Salts: A Systematic Review of the Potential Hazards of These Invaluable Preservatives and the Expanding Spectrum of Clinical Uses for Sodium Benzoate
Joseph Piper, Peter W. Piper
Comprehensive Reviews in Food Science and Food Safety (2017) Vol. 16, Iss. 5, pp. 868-880
Open Access | Times Cited: 159
Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Chieh‐Hsin Lin, Ching-Hua Lin, Yue-Cune Chang, et al.
Biological Psychiatry (2017) Vol. 84, Iss. 6, pp. 422-432
Closed Access | Times Cited: 125
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms
Joshua T. Kantrowitz, Michael L. Epstein, Migyung Lee, et al.
Schizophrenia Research (2017) Vol. 191, pp. 70-79
Closed Access | Times Cited: 118
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
W. Wolfgang Fleischhacker, Jana Podhorná, Martina Gröschl, et al.
The Lancet Psychiatry (2021) Vol. 8, Iss. 3, pp. 191-201
Closed Access | Times Cited: 104
The Effects of Acupuncture on Glutamatergic Neurotransmission in Depression, Anxiety, Schizophrenia, and Alzheimer's Disease: A Review of the Literature
Cheng‐Hao Tu, Iona MacDonald, Yi‐Hung Chen
Frontiers in Psychiatry (2019) Vol. 10
Open Access | Times Cited: 79
Glutamatergic dysfunction in Schizophrenia
Andreas O. Kruse, Juan Bustillo
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 67
Microglia and cognitive impairment in schizophrenia: translating scientific progress into novel therapeutic interventions
Chuanjun Zhuo, Hongjun Tian, Xueqin Song, et al.
Schizophrenia (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 34
Therapeutic Potential of DAAO Inhibitors for Cognitive Impairment Associated with Schizophrenia: Learnings from Luvadaxistat
Ryan T. Terry-Lorenzo, Ruicheng Fan, Ni A. Khin, et al.
The International Journal of Neuropsychopharmacology (2025)
Open Access | Times Cited: 1
Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review
Abigail Gee, Paola Dazzan, Anthony A. Grace, et al.
Translational Psychiatry (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme
Dragana Bugarski‐Kirola, Nakao Iwata, Snjezana Sameljak, et al.
The Lancet Psychiatry (2016) Vol. 3, Iss. 12, pp. 1115-1128
Closed Access | Times Cited: 79
Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
Igne Sinkeviciute, Marieke J.H. Begemann, Merel Prikken, et al.
Schizophrenia (2018) Vol. 4, Iss. 1
Open Access | Times Cited: 79
Gut Microbiota-Based Pharmacokinetics and the Antidepressant Mechanism of Paeoniflorin
Jinbo Yu, Zhen‐Xiong Zhao, Ran Peng, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 70
The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review
Ragy R. Girgis, Anthony W. Zoghbi, Daniel C. Javitt, et al.
Journal of Psychiatric Research (2018) Vol. 108, pp. 57-83
Closed Access | Times Cited: 68
The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders
Bahareh Peyrovian, Joshua D. Rosenblat, Zihang Pan, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2019) Vol. 92, pp. 387-404
Closed Access | Times Cited: 63
Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia
Chieh‐Hsin Lin, Ping-Kun Chen, Shi‐Heng Wang, et al.
JAMA Network Open (2021) Vol. 4, Iss. 4, pp. e216156-e216156
Open Access | Times Cited: 43
Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial
Chieh‐Hsin Lin, Shi‐Heng Wang, Hsien‐Yuan Lane
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 7, pp. 545-555
Open Access | Times Cited: 32
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
Andrea de Bartolomeis, Licia Vellucci, Mark C. Austin, et al.
Biomolecules (2022) Vol. 12, Iss. 7, pp. 909-909
Open Access | Times Cited: 30
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 18
Finding the Right Dose: NMDA Receptor–Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement
Pejman Sehatpour, Joshua T. Kantrowitz
Biological Psychiatry (2024) Vol. 97, Iss. 2, pp. 128-138
Closed Access | Times Cited: 7
Potential and Challenges for the Clinical Use of d-Serine As a Cognitive Enhancer
Gerson D. Guercio, Rogério Panizzutti
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 56
Neurobiology of glycine transporters: From molecules to behavior
Bruno Lemes Marques, Onésia Cristina Oliveira‐Lima, Gustavo Almeida Carvalho, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 118, pp. 97-110
Closed Access | Times Cited: 43
Page 1 - Next Page

Scroll to top